GLP-1 peptide analogs for targeting pancreatic beta cells

Seyed Ebrahim Alavi; Hasan Ebrahimi Shahmabadi

doi:10.1016/j.drudis.2021.03.032

GLP-1 peptide analogs for targeting pancreatic beta cells

Seyed Ebrahim Alavi, Hasan Ebrahimi Shahmabadi

Western Sydney University

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Abstract

Loss or dysfunction of the pancreatic beta cells or insulin receptors leads to diabetes mellitus (DM). This usually occurs over many years; therefore, the development of methods for the timely detection and clinical intervention are vital to prevent the development of this disease. Glucagon-like peptide-1 receptor (GLP-1R) is the receptor of GLP-1, an incretin hormone that causes insulin secretion in a glucose-dependent manner. GLP-1R is highly expressed on the surface of pancreatic beta cells, providing a potential target for bioimaging. In this review, we provide an overview of various strategies, such as the development of GLP-1R agonists (e.g., exendin-4), and GLP-1 sequence modifications for GLP-1R targeting for the diagnosis and treatment of pancreatic beta cell disorders. We also discuss the challenges of targeting pancreatic beta cells and strategies to address such challenges.

Original language	English
Pages (from-to)	1936-1943
Number of pages	8
Journal	Drug Discovery Today
Volume	26
Issue number	8
DOIs	https://doi.org/10.1016/j.drudis.2021.03.032
Publication status	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2021.03.032

Cite this

@article{38e8cfdff1134eda8f0894f10d900446,

title = "GLP-1 peptide analogs for targeting pancreatic beta cells",

abstract = "Loss or dysfunction of the pancreatic beta cells or insulin receptors leads to diabetes mellitus (DM). This usually occurs over many years; therefore, the development of methods for the timely detection and clinical intervention are vital to prevent the development of this disease. Glucagon-like peptide-1 receptor (GLP-1R) is the receptor of GLP-1, an incretin hormone that causes insulin secretion in a glucose-dependent manner. GLP-1R is highly expressed on the surface of pancreatic beta cells, providing a potential target for bioimaging. In this review, we provide an overview of various strategies, such as the development of GLP-1R agonists (e.g., exendin-4), and GLP-1 sequence modifications for GLP-1R targeting for the diagnosis and treatment of pancreatic beta cell disorders. We also discuss the challenges of targeting pancreatic beta cells and strategies to address such challenges.",

author = "Alavi, {Seyed Ebrahim} and Shahmabadi, {Hasan Ebrahimi}",

year = "2021",

doi = "10.1016/j.drudis.2021.03.032",

language = "English",

volume = "26",

pages = "1936--1943",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier : Trends Journals",

number = "8",

}

TY - JOUR

T1 - GLP-1 peptide analogs for targeting pancreatic beta cells

AU - Alavi, Seyed Ebrahim

AU - Shahmabadi, Hasan Ebrahimi

PY - 2021

Y1 - 2021

N2 - Loss or dysfunction of the pancreatic beta cells or insulin receptors leads to diabetes mellitus (DM). This usually occurs over many years; therefore, the development of methods for the timely detection and clinical intervention are vital to prevent the development of this disease. Glucagon-like peptide-1 receptor (GLP-1R) is the receptor of GLP-1, an incretin hormone that causes insulin secretion in a glucose-dependent manner. GLP-1R is highly expressed on the surface of pancreatic beta cells, providing a potential target for bioimaging. In this review, we provide an overview of various strategies, such as the development of GLP-1R agonists (e.g., exendin-4), and GLP-1 sequence modifications for GLP-1R targeting for the diagnosis and treatment of pancreatic beta cell disorders. We also discuss the challenges of targeting pancreatic beta cells and strategies to address such challenges.

AB - Loss or dysfunction of the pancreatic beta cells or insulin receptors leads to diabetes mellitus (DM). This usually occurs over many years; therefore, the development of methods for the timely detection and clinical intervention are vital to prevent the development of this disease. Glucagon-like peptide-1 receptor (GLP-1R) is the receptor of GLP-1, an incretin hormone that causes insulin secretion in a glucose-dependent manner. GLP-1R is highly expressed on the surface of pancreatic beta cells, providing a potential target for bioimaging. In this review, we provide an overview of various strategies, such as the development of GLP-1R agonists (e.g., exendin-4), and GLP-1 sequence modifications for GLP-1R targeting for the diagnosis and treatment of pancreatic beta cell disorders. We also discuss the challenges of targeting pancreatic beta cells and strategies to address such challenges.

UR - http://hdl.handle.net/1959.7/uws:59620

U2 - 10.1016/j.drudis.2021.03.032

DO - 10.1016/j.drudis.2021.03.032

M3 - Article

SN - 1359-6446

VL - 26

SP - 1936

EP - 1943

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 8

ER -

GLP-1 peptide analogs for targeting pancreatic beta cells

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this